FSSAI opens three cases against Nestlé India over infant-food claims
India’s food regulator has initiated three adjudication cases involving claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, including “5 HMOs” and “easy-to-digest” whey. A separate matter concerns alleged sub-standard biotin content in a follow-up formula; no final penalty has been announced.
What happened
FSSAI initiated three adjudication cases against Nestle India over promotional claims on NAN Excella Pro Stage 1 and Lactogen Pro 1, plus alleged sub-standard
Key facts
- Three separate adjudication cases
- Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020
- Section 3 of the Infant Milk Substitutes, Feeding Bottles and Infant Foods Act, 1992
What changed
FSSAI initiated three adjudication cases against Nestle India over promotional claims on NAN Excella Pro Stage 1 and Lactogen Pro 1, plus alleged sub-standard biotin content in a follow-up formula. No final penalty has been stated.
Why this matters
Nestlé India should urgently audit infant-formula claims, substantiation and nutrient-quality controls as FSSAI’s three cases raise immediate compliance and brand-trust risks.
What to watch
- FSSAI adjudication notices, hearing dates, final orders, penalties, recalls, or stop-sale directions.
- Whether FSSAI challenges only named SKUs or broadens review to other Nestlé infant and young-child nutrition products.
- Evidence submitted on the scientific basis for '5 HMOs' and 'easy-to-digest' claims.
- Follow-up testing results and the severity of the alleged biotin shortfall.
- Changes in sales velocity, e-commerce ratings, pediatrician sentiment, or competitor advertising in infant formula.